首頁/REGN

公开研究页

行情来自市场数据接口；下方公司研究基于已核验公开来源，但不等同于实时、个性化的 AI 投资结论。

去工作台分析 REGN
REGNNASDAQ/health care

Regeneron Pharmaceuticals, Inc.

$663.09下跌-1,43 (-0,22%)
研究复核截至: 2026年7月12日 上午12:00 [UTC]
研究概览近 3 个月价格投资论点关键催化剂最新财报研究近期新闻数据与研究来源

研究概览

Regeneron Pharmaceuticals, Inc. operates in Biotechnology within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Ouverture
661,63
Haut
665,60
Bas
655,11
Capitalisation
69,52 Md
Ratio C/B
16.20
Plus haut sur 52 semaines
--
Dividende
0.570%
Dividende trimestriel
--

近 3 个月价格

這裡展示近 3 個月價格走勢，幫助使用者先理解短期結構，再決定是否進入完整研究工作台。

投资论点

基础情景
New indications, age groups and geographies can extend a broad type-2 inflammation franchise. The base case remains conditional on retinal competition staying manageable.
多头情景
New indications, age groups and geographies can extend a broad type-2 inflammation franchise. Longer dosing intervals can support retinal share and physician adoption despite biosimilar entry. Bispecific antibodies, immunology assets and genetic medicines offer multiple routes to portfolio expansion.
空头情景
Biosimilars and rival long-duration therapies can erode EYLEA volume, pricing and share. Profit-sharing and dependence on collaborators shape the cash economics of major products. Late-stage oncology and immunology programs may fail to show sufficient efficacy or safety.
论点失效条件
Reassess the thesis if biosimilars and rival long-duration therapies can erode EYLEA volume, pricing and share.

关键催化剂

  • Dupixent expansion

    New indications, age groups and geographies can extend a broad type-2 inflammation franchise.

  • EYLEA HD conversion

    Longer dosing intervals can support retinal share and physician adoption despite biosimilar entry.

  • Internal pipeline

    Bispecific antibodies, immunology assets and genetic medicines offer multiple routes to portfolio expansion.

主要风险

  • Retinal competition

    Biosimilars and rival long-duration therapies can erode EYLEA volume, pricing and share.

  • Partner economics

    Profit-sharing and dependence on collaborators shape the cash economics of major products.

  • Pipeline attrition

    Late-stage oncology and immunology programs may fail to show sufficient efficacy or safety.

最新财报研究

Q1 2026

Regeneron's first-quarter 2026 update highlighted Dupixent's continued global expansion, execution across the EYLEA HD retinal franchise and investment in oncology, immunology and genetic-medicine programs.

估值解读

  • Dupixent durability and successful EYLEA HD conversion anchor value while retinal competition remains a material offset.
  • The internal pipeline deserves option value, but commercialization and partner economics require asset-by-asset risk adjustment.

同行比较入口

ABBVAMGNGILD

近期新闻

Trefis · il y a 8 heures

Own Regeneron For Biotech Growth? Incyte Is Making Its Case.

Insider Monkey · il y a 11 heures

Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2

MT Newswires · il y a 5 jours

Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says

Insider Monkey · il y a 5 jours

Is Regeneron Pharmaceuticals, Inc. (REGN) Stock Still a Biotech Leader After Analyst Price Target Cut?

Trefis · il y a 6 jours

Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside

24/7 Wall St. · il y a 6 jours

Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”

数据与研究来源

研究更新: 2026年7月12日 上午12:00 [UTC]
3 个已核验来源
Regeneron Reports First Quarter 2026 Financial and Operating ResultsRegeneron Pharmaceuticals, Inc. · earnings已核验

抓取时间: 2026/7/12 上午12:00:00 [UTC]

发布时间: 2026/4/30 上午12:00:00

查看原始来源
Regeneron Pharmaceuticals, Inc. Investor RelationsRegeneron Pharmaceuticals, Inc. · company已核验

抓取时间: 2026/7/12 上午12:00:00 [UTC]

查看原始来源
Regeneron SEC filings and company factsU.S. Securities and Exchange Commission · filing已核验

抓取时间: 2026/7/12 上午12:00:00 [UTC]

发布时间: 2026/4/30 上午12:00:00

查看原始来源

在工作台中继续研究

保留 REGN，运行多智能体分析并持续跟踪论点变化。

免费分析 REGN

探索完整研究體系

每個階段職責明確，並為下一階段留下可追溯的輸出。

研究方法論閱讀市場報告瀏覽股票

继续深挖这只股票

市場分析 Agent

負責先判断价格結構、趋势强弱與交易節奏有没有支持 thesis。

基本面分析 Agent

負責判断公司的业务质量、盈利結構與财务健康度。

新闻分析 Agent

追踪最近发生了什么，以及這些事件是否真的改变 thesis。

風險经理 Agent

負責在風險辩論后给出最终風險等級和执行邊界。